Mrv1909 01012021052D 19 20 0 0 0 0 999 V2000 -4.0042 -0.3365 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 -3.2897 0.0759 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -3.2897 0.9009 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 -2.5753 -0.3365 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 -1.8608 0.0759 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.1463 -0.3365 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -0.4319 0.0759 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 0.2824 -0.3365 0.0000 C 0 0 2 0 0 0 0 0 0 0 0 0 0.2824 -1.1615 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 0.9970 -1.5740 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 1.7115 -1.1615 0.0000 C 0 0 1 0 0 0 0 0 0 0 0 0 1.7115 -0.3365 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 0.9970 0.0759 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 2.4961 -1.4164 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 2.9810 -0.7490 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 2.4961 -0.0815 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 0.9970 -2.3990 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 0.9970 0.9009 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 1.7977 -1.9819 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0 5 6 1 0 0 0 0 6 7 1 0 0 0 0 8 7 1 1 0 0 0 10 11 1 0 0 0 0 8 13 1 0 0 0 0 14 15 1 0 0 0 0 15 16 1 0 0 0 0 11 14 1 0 0 0 0 13 18 2 0 0 0 0 10 17 2 0 0 0 0 2 3 2 0 0 0 0 1 2 1 0 0 0 0 2 4 1 0 0 0 0 4 5 1 0 0 0 0 9 10 1 0 0 0 0 9 8 1 0 0 0 0 11 12 1 0 0 0 0 12 13 1 0 0 0 0 12 16 1 0 0 0 0 11 19 1 6 0 0 0 M END > DB04433 > drugbank > [H][C@@]12CCCN1C(=O)[C@H](CCCNC(N)=N)NC2=O > InChI=1S/C11H19N5O2/c12-11(13)14-5-1-3-7-10(18)16-6-2-4-8(16)9(17)15-7/h7-8H,1-6H2,(H,15,17)(H4,12,13,14)/t7-,8-/m0/s1 > ZRJHYOXNWCMGMW-YUMQZZPRSA-N > C11H19N5O2 > 253.3009 > 253.153874877 > 5 > 37 > 0.9999396592555184 > 26.68446130424735 > 1 > 4 > 0 > 0 > N-{3-[(3S,8aS)-1,4-dioxo-octahydropyrrolo[1,2-a]pyrazin-3-yl]propyl}guanidine > -2.17 > -2.140307920858981 > -2.20 > 0 > 1 > 2 > 1 > 11.271356554777084 > 12.166326854994079 > 111.31 > 75.7097 > 4 > 1 > 1.60e+00 g/l > 2-amino-3H,5H-pyrrolo[3,2-d]pyrimidin-4-one > 0 > DB04433 > EXPT00499 > experimental > Verpacamide A > Cyclo-(L-arginine-L-proline) inhibitor $$$$